Home » Business » Manufacturing
Medicinal boost
By Ding Yining |
May 8, 2010, Saturday
|
Print Edition
Print Edition
BOEHRINGER Ingelheim expects its sales in China to grow about 45 percent to 1.76 billion yuan (US$257 million) this year as it expands its product portfolio and a boom in demand in China's rural areas.
The German drug maker's global sales last year rose 9.7 percent to 12.7 billion euros (US$16.2 billion).
"China is expected to contribute about 15 percent to our global sales growth this year and will account for around 50 percent of growth in emerging markets around the globe," said David Preston, general manager of Boehringer Ingelheim Shanghai Pharmaceuticals Co. "We're also actively in talks with several local companies for merger and acquisition deals to increase our over-the-counter products and even traditional Chinese medicine."
The company is also planning to introduce six innovative drugs to treat oncology and diabetes during 2013 and 2015.
The German drug maker's global sales last year rose 9.7 percent to 12.7 billion euros (US$16.2 billion).
"China is expected to contribute about 15 percent to our global sales growth this year and will account for around 50 percent of growth in emerging markets around the globe," said David Preston, general manager of Boehringer Ingelheim Shanghai Pharmaceuticals Co. "We're also actively in talks with several local companies for merger and acquisition deals to increase our over-the-counter products and even traditional Chinese medicine."
The company is also planning to introduce six innovative drugs to treat oncology and diabetes during 2013 and 2015.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
